In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Awakn Life Sciences (AWKNF – Research Report), with a price target of $10.00. The company's shares closed last Wednesday at $0.35, equals to its 52-week low of $0.35. According to TipRanks.com, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.6% and a 30.6% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals. Currently, the analyst consensus on Awakn Life Sciences is a Moderate Buy with an average price target of $8.10.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-their-buy-rating-on-awakn-life-sciences-awknf?utm_source=advfn.com&utm_medium=referral
Awakn Life Sciences (QB) (USOTC:AWKNF)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Awakn Life Sciences (QB) Charts.
Awakn Life Sciences (QB) (USOTC:AWKNF)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Awakn Life Sciences (QB) Charts.